News stories about Viveve Medical (NASDAQ:VIVE) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Viveve Medical earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave news articles about the company an impact score of 44.9188998623462 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

VIVE has been the topic of a number of analyst reports. Cowen set a $11.00 price objective on shares of Viveve Medical and gave the company a “buy” rating in a research report on Monday, October 23rd. Mizuho initiated coverage on shares of Viveve Medical in a research report on Thursday, November 16th. They set a “buy” rating and a $10.00 price target on the stock. ValuEngine cut shares of Viveve Medical from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Northland Securities initiated coverage on shares of Viveve Medical in a research report on Friday, January 5th. They set an “outperform” rating and a $8.00 price target on the stock. Finally, Ladenburg Thalmann Financial Services reiterated a “buy” rating on shares of Viveve Medical in a research report on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. Viveve Medical presently has an average rating of “Buy” and an average price target of $10.00.

Shares of Viveve Medical (NASDAQ:VIVE) traded down $0.09 during midday trading on Friday, hitting $4.89. 133,603 shares of the company traded hands, compared to its average volume of 119,614. Viveve Medical has a one year low of $3.75 and a one year high of $11.16. The company has a debt-to-equity ratio of 2.72, a current ratio of 3.89 and a quick ratio of 3.63. The stock has a market capitalization of $94.99, a PE ratio of -2.26 and a beta of -0.66.

Viveve Medical (NASDAQ:VIVE) last announced its quarterly earnings results on Wednesday, November 8th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.08). Viveve Medical had a negative net margin of 257.58% and a negative return on equity of 275.77%. The company had revenue of $4.07 million for the quarter, compared to analysts’ expectations of $4.10 million. During the same quarter in the prior year, the firm earned ($0.46) EPS. Viveve Medical’s quarterly revenue was up 120.1% compared to the same quarter last year. equities analysts anticipate that Viveve Medical will post -2.05 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This report was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.watchlistnews.com/viveve-medical-vive-given-coverage-optimism-score-of-0-09/1806984.html.

About Viveve Medical

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Insider Buying and Selling by Quarter for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.